Is APLT or PMVP more profitable?

PMV Pharmaceuticals' return on equity of -68.98% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% PMV Pharmaceuticals N/A -68.98% -62.70%

Which has preferable earnings and valuation, OKYO or APLT?

OKYO Pharma has higher earnings, but lower revenue than Applied Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$4.71M N/A N/A Applied Therapeutics $1M 15.86 -$105.62M -$0.10 N/A

Is OKYO or APLT more profitable?

OKYO Pharma's return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Applied Therapeutics N/A -340.84% -175.00%

Do analysts prefer EXOZ or APLT?

Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is EXOZ or APLT more profitable?

eXoZymes' return on equity of -220.63% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Applied Therapeutics N/A -340.84% -175.00%

Is INKT or APLT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% Applied Therapeutics N/A -340.84% -175.00%

Applied Therapeutics (APLT) Competitors

$0.10 0.00 (0.00%)

As of 06/29/2026

Compare

APLT vs. PMVP, OKYO, EXOZ, INKT, and XLO

Should you buy Applied Therapeutics stock or one of its competitors? MarketBeat compares Applied Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Applied Therapeutics include PMV Pharmaceuticals (PMVP), OKYO Pharma (OKYO), eXoZymes (EXOZ), MiNK Therapeutics (INKT), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical products" industry.

How does Applied Therapeutics compare to PMV Pharmaceuticals?

Applied Therapeutics (NASDAQ:APLT) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

PMV Pharmaceuticals has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

Applied Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 870.87%. PMV Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 280.23%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

PMV Pharmaceuticals' return on equity of -68.98% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

In the previous week, PMV Pharmaceuticals had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for PMV Pharmaceuticals and 0 mentions for Applied Therapeutics. PMV Pharmaceuticals' average media sentiment score of 0.96 beat Applied Therapeutics' score of 0.00 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
PMV Pharmaceuticals	Positive

Summary

PMV Pharmaceuticals beats Applied Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Applied Therapeutics compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

OKYO Pharma's return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Applied Therapeutics	N/A	-340.84%	-175.00%

In the previous week, OKYO Pharma had 3 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for OKYO Pharma and 0 mentions for Applied Therapeutics. OKYO Pharma's average media sentiment score of 0.45 beat Applied Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
OKYO Pharma	Neutral
Applied Therapeutics	Neutral

OKYO Pharma has higher earnings, but lower revenue than Applied Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$4.71M	N/A	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

OKYO Pharma presently has a consensus price target of $6.33, indicating a potential upside of 325.06%. Applied Therapeutics has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

OKYO Pharma has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

OKYO Pharma beats Applied Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Applied Therapeutics compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, eXoZymes had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for eXoZymes and 0 mentions for Applied Therapeutics. eXoZymes' average media sentiment score of 1.19 beat Applied Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the media.

Company	Overall Sentiment
eXoZymes	Positive
Applied Therapeutics	Neutral

eXoZymes' return on equity of -220.63% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Applied Therapeutics	N/A	-340.84%	-175.00%

eXoZymes has a beta of 2.66, meaning that its share price is 166% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

98.3% of Applied Therapeutics shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

eXoZymes has higher earnings, but lower revenue than Applied Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	1,073.33	-$9.16M	-$1.14	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Summary

eXoZymes beats Applied Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Applied Therapeutics compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

MiNK Therapeutics currently has a consensus price target of $35.00, suggesting a potential upside of 193.33%. Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, MiNK Therapeutics had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Applied Therapeutics. MiNK Therapeutics' average media sentiment score of 1.89 beat Applied Therapeutics' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MiNK Therapeutics	Very Positive
Applied Therapeutics	Neutral

MiNK Therapeutics has higher earnings, but lower revenue than Applied Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

MiNK Therapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Applied Therapeutics	N/A	-340.84%	-175.00%

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MiNK Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market.

Summary

MiNK Therapeutics beats Applied Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Applied Therapeutics compare to Xilio Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Applied Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Xilio Therapeutics' return on equity of -151.42% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Applied Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Xilio Therapeutics has a consensus price target of $28.00, indicating a potential upside of 189.56%. Given Applied Therapeutics' higher possible upside, equities research analysts plainly believe Applied Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Xilio Therapeutics had 3 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for Xilio Therapeutics and 0 mentions for Applied Therapeutics. Xilio Therapeutics' average media sentiment score of 0.71 beat Applied Therapeutics' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Xilio Therapeutics	Positive

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Xilio Therapeutics has higher revenue and earnings than Applied Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Xilio Therapeutics	$53.48M	1.19	-$35.04M	-$3.55	N/A

Summary

Xilio Therapeutics beats Applied Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Applied Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLT vs. The Competition

Export

Metric	Applied Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.86M	$3.65B	$6.78B	$12.58B
Dividend Yield	N/A	2.21%	2.66%	6.21%
P/E Ratio	-1.03	21.25	27.32	24.86
Price / Sales	15.86	340.58	561.22	117.20
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	0.21	8.81	11.08	6.58
Net Income	-$105.62M	$23.81M	$3.57B	$336.70M
7 Day Performance	N/A	4.01%	2.62%	3.29%
1 Month Performance	N/A	1.98%	0.95%	1.72%
1 Year Performance	-66.89%	70.53%	37.04%	31.91%

Applied Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLT Applied Therapeutics	N/A	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
PMVP PMV Pharmaceuticals	3.5015 of 5 stars	$1.15 -2.5%	$5.00 +334.8%	+20.6%	$62.93M	N/A	N/A	50
OKYO OKYO Pharma	2.9567 of 5 stars	$1.54 -0.6%	$6.33 +311.3%	-38.0%	$62.86M	N/A	N/A	7
EXOZ eXoZymes	0.9134 of 5 stars	$7.40 +3.6%	N/A	-19.0%	$60.54M	$70K	N/A	29	Positive News
INKT MiNK Therapeutics	3.3682 of 5 stars	$11.31 -6.6%	$35.00 +209.5%	+70.6%	$60.33M	N/A	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLT) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Applied Therapeutics (APLT) Competitors

APLT vs. PMVP, OKYO, EXOZ, INKT, and XLO

How does Applied Therapeutics compare to PMV Pharmaceuticals?

Summary

How does Applied Therapeutics compare to OKYO Pharma?

Summary

How does Applied Therapeutics compare to eXoZymes?

Summary

How does Applied Therapeutics compare to MiNK Therapeutics?

Summary

How does Applied Therapeutics compare to Xilio Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Applied Therapeutics (APLT) Competitors

APLT vs. PMVP, OKYO, EXOZ, INKT, and XLO

How does Applied Therapeutics compare to PMV Pharmaceuticals?

Which has stronger earnings and valuation, APLT or PMVP?

Do institutionals and insiders believe in APLT or PMVP?

Which has more risk & volatility, APLT or PMVP?

Do analysts recommend APLT or PMVP?

Is APLT or PMVP more profitable?

Does the media refer more to APLT or PMVP?

Summary

How does Applied Therapeutics compare to OKYO Pharma?

Is OKYO or APLT more profitable?

Does the media favor OKYO or APLT?

Which has preferable earnings and valuation, OKYO or APLT?

Do analysts rate OKYO or APLT?

Which has more risk and volatility, OKYO or APLT?

Do insiders & institutionals believe in OKYO or APLT?

Summary

How does Applied Therapeutics compare to eXoZymes?

Do analysts prefer EXOZ or APLT?

Does the media prefer EXOZ or APLT?

Is EXOZ or APLT more profitable?

Which has more volatility and risk, EXOZ or APLT?

Do insiders & institutionals have more ownership in EXOZ or APLT?

Which has higher earnings and valuation, EXOZ or APLT?

Summary

How does Applied Therapeutics compare to MiNK Therapeutics?

Do analysts rate INKT or APLT?

Does the media prefer INKT or APLT?

Which has preferable valuation and earnings, INKT or APLT?

Is INKT or APLT more profitable?

Do insiders and institutionals hold more shares of INKT or APLT?

Which has more risk & volatility, INKT or APLT?

Summary

How does Applied Therapeutics compare to Xilio Therapeutics?

Is APLT or XLO more profitable?

Do analysts recommend APLT or XLO?

Does the media refer more to APLT or XLO?

Do insiders and institutionals have more ownership in APLT or XLO?

Which has more risk and volatility, APLT or XLO?

Which has stronger valuation & earnings, APLT or XLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools